Tuesday, 19 Nov 2019

You are here

Oral Anticoagulation Effective Following Hip and Knee Replacement Surgery

Many protocols call for anticoagulation after total hip or total knee arthroplasty to prevent venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism), and some reports have suggested a role for aspiring or direct oral anticoagulants as preventative therapy.

Patients undergoing total hip or knee arthroplasty were given oral rivaroxaban (Xarelto) 10 mg until postoperative day 5 and then were randomly assigned to continue rivaroxaban (RIX) or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty (TKA) or for 30 days after total hip arthroplasty (THA). The primary outcome was venous thromboembolism by 90 days. 

They enrolled 3424 patients (1804 THA and 1620 TKA) were enrolled in the trial. There was no difference in the frequency of venous thromboembolism in the ASA patients (0.64%) and RIX patients (0.70%).

There was no significant difference in major bleeding complications with ASA (0.47%) or RIX (0.29%) post-operatively.

These results suggest that extended prophylaxis with either ASA or RIX was equally effective after an initial 5 days course of RIX following THA or TKA, thereby demonstrating effective prevention of venous thromboembolism with oral direct anticoagulation. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.